Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer
Krishan R. Jethwa(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Benjamin R. Kipp(Mayo Clinic in Arizona), Samuel Jang(WinnMed), M. Petersen(Mayo Clinic in Arizona), Thomas J. Whitaker(Mayo Clinic), Harigopal Sandhyavenu(Mayo Clinic), Trey C. Mullikin(Cancer Institute (WIA)), William S. Harmsen(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Lindsey Waltman(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Sean S. Park(Mayo Clinic), Kenneth R. Olivier(Mayo Clinic), Joleen M. Hubbard(Rutgers, The State University of New Jersey)
Cited by 37
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2017|357